Work

Supplementary Figure S2 from KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial

Year: 2025

Type: supplementary-materials

Abstract: Kaplan-Meier estimates of recurrence-free survival of patients with KIT exon 11 substitution mutation (A) and patients with KIT exon 9 mutation (B). The 5-year and 10-year survival rates are shown. Censored patients are indicated with a bar

DOI: 10.1158/1078-0432.30708669

Authors: Heikki Joensuu, Eva Wardelmann, Mikael Eriksson, Annette Reichardt, Kirsten Sundby Hall, Jochen Schütte, Silke Cameron, Peter Hohenberger, Harri Sihto, Philipp J. Jost, Lars H. Lindner, Sebastian Bauer, Bengt Nilsson, Raija Kallio, Tommi Pesonen, Peter Reichardt

Language: English

Topic: Gastrointestinal Tumor Research and Treatment

Subfield: Gastroenterology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4416629771

Cites:

Cited by:

Related to: 10